Patient Enrolled in Phase 2 Trial of Experimental Therapy AP-101

Patient Enrolled in Phase 2 Trial of Experimental Therapy AP-101

312802

Patient Enrolled in Phase 2 Trial of Experimental Therapy AP-101

A Phase 2 clinical trial evaluating AL-S Pharma AG’s experimental therapy AP-101 in people with amyotrophic lateral sclerosis (ALS) has enrolled its first patient. The study (NCT05039099) already is recruiting up to 63 adults with sporadic and SOD1-related familial ALS at one of its Canadian sites. Other sites in Canada, as well as in the U.S. and Sweden, are planned to start enrolling; more information is available here. Top-line data are expected by mid-2023. The trial’s start…

You must be logged in to read/download the full post.